Genentech Highlights Giredestrant's Potential in Early Breast Cancer at ASCO 2026
Event summary
- Genentech will present new data on giredestrant, an investigational oral SERD, at ASCO 2026, reinforcing its potential as a future standard of care in early breast cancer.
- Three Phase III trials (lidERA, persevERA, evERA) will provide updated efficacy and safety data for giredestrant across different disease stages and patient populations.
- The FDA has accepted a New Drug Application for giredestrant based on positive evERA trial data.
- Genentech will also present data on other investigational and approved medicines, including RG6596/ZN-A-1041 for HER2-positive breast cancer and divarasib for non-small cell lung cancer.
The big picture
Genentech's focus on giredestrant at ASCO 2026 underscores the company's commitment to transforming the treatment paradigm in early breast cancer. The potential approval of giredestrant could significantly impact the endocrine therapy landscape, particularly for ER-positive, HER2-negative breast cancer, which accounts for approximately 70% of cases. The broader oncology market is increasingly focused on targeted therapies and combination treatments, and Genentech's data could reinforce its leadership in this area.
What we're watching
- Regulatory Progress
- Whether the FDA will approve giredestrant based on the lidERA and evERA trial data presented at ASCO 2026.
- Clinical Efficacy
- The consistency of giredestrant's efficacy and safety across pre- and post-menopausal patients with early breast cancer.
- Competitive Landscape
- How Genentech's data on giredestrant and other investigational medicines will position it against competitors in the breast cancer treatment space.
Related topics